Forte contends that cell therapy can potentially address unmet medical needs in orthopedics such as incomplete fracture healing, which affects hundreds of thousands of patients worldwide. Bone Therapeutics remains on target for delivery of topline results in early 2023 for its Phase IIB study of its allogeneic cell therapy product, ALLOB, in patients with difficult tibial fractures.

"A complicated tibial fracture that doesn't heal costs upwards of $30,000," Forte said. "If we're able to transform a complicated fracture into an uncomplicated fracture by using these cells to accelerate the regeneration, we're making $20,000 [in] savings."

Watch the video below to learn more.

ISCT president calls for cell and gene therapy education, training amid ‘talent shortage’
This week in San Francisco, industry, investors, physicians, patients, and regulators convened at the International Society for Cell & Gene Therapy (ISCT)...

ISCT working group weighs in on expanded access to CGT
Patricia Zettler, JD, associate professor of law at The Ohio State University, and chair of the International Society for Cell & Gene Therapy (ISCT) Expanded...

ISCT22: Tackling the ethical issues around cell and gene therapy
Unproven and unethical cell and gene therapies are a growing problem worldwide, according to Laertis Ikonomou, PhD, of the Department of Oral Biology...

Bone Therapeutics, Link Health enter agreement for rights of ALLOB
Bone Therapeutics and Link Health Pharma have signed a nonbinding agreement for the global rights regarding the development, manufacturing, and commercialization...